ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · RMD Open · 2026-08-20

In 308 adults with DMARD-naïve rheumatoid arthritis, a tailored treat-to-target strategy (first DMARD by autoantibody status, intensification at 1 month) was not superior to routine care: ts/bDMARD use at 10 months 21% vs 17%; mean DAS similar.

RCTn = 308
Looijen et al. Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management-a multicentre, randomised, open-label trial
Rheumatology · Osteoarthritis Cartilage · 2026-07-07

Secondary analysis of 87 PROMOTE trial participants with painful knee osteoarthritis: on methotrexate, IL-8 and TNF-α fell and IL-15 rose; higher baseline IFN-γ and falling TNF-α were linked to greater pain reduction. Only hs-CRP showed consistent treatment-by-marker effects.

Secondary analysisn = 87
Liang et al. Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial
Rheumatology · Lancet Rheumatol · 2026-07-02

5-year follow-up of 120 of 236 adults with arthralgia at increased RA risk: glucocorticoid injection plus 1 year of methotrexate vs placebo cut RA in ACPA-negative (9% vs 32%; HR 0·24) but not ACPA-positive people (58% vs 65%; HR 0·75); no clear effect in full cohort.

RCTn = 236
Mulligen et al. Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial
Rheumatology · RMD Open · 2026-05-28

In 85 patients with early undifferentiated arthritis given a glucocorticoid injection, 3 months of baricitinib improved DAS more than NSAIDs (adjusted difference −0.52; p=0.01); methotrexate's gain was non-significant (−0.39; p=0.09). No significant difference at 12 months.

RCTn = 85
Nevins et al. Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritis
Rheumatology · Ann Rheum Dis · 2026-02-28

In 144 patients with rheumatoid arthritis in remission or low disease activity, neither ozoralizumab spacing (79.2%) nor methotrexate dose reduction (72.7%) was noninferior to continued treatment (97.9%) for keeping low disease activity at week 48.

RCTn = 144
Imai et al. Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)
Rheumatology · Semin Arthritis Rheum · 2026-01-12

Post hoc analysis of AVERT and AVERT-2 (ACPA-positive early RA): DAS28-CRP remission at 6/12 months was 27%/39% with methotrexate (n=388) and 43%/53% with abatacept plus methotrexate (n=743); only baseline DAS28 and early response consistently predicted remission.

Secondary analysis
Bergstra et al. Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.